Compare · IBO vs NVO
IBO vs NVO
Side-by-side comparison of Impact BioMedical Inc. (IBO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $174.57B, about 3274.7x IBO ($53.3M).
- IBO has been more active in the news (17 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for IBO).
- Company
- Impact BioMedical Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $53.3M
- $174.57B
- 1M return
- -
- +0.27%
- 1Y return
- -
- -19.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2024
- News (4w)
- 17
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IBO
- Impact BioMedical Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Impact BioMedical Inc.
- Impact BioMedical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Impact BioMedical Inc.
- Chief Operating Officer Suseck Mark gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Zimmerman Christian Thomas gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Hibbert Castel Berisford gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Sims Melissa Kaye gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Keene David K gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Brownell Elise gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S